NEOS News and Press, Neos Therapeutics Inc. From 12/31/20

Long-term investors in Aytu BioScience have endured a series of value and confidence eroding actions by the company over the last 12 months including dilution and reverse splits. Aytu has significant upside potential and numerous exciting catalysts to be announced that could drive sig...

Gainers: Immutep (IMMP) +166%.SELLAS Life Sciences (SLS) +90%.Neos Therapeutics (NEOS) +65%.Greenwich LifeSciences (GLSI) +51%.Aytu BioScience (AYTU) +34%.Veru (VERU) +34%.Silver Spike Acquisition (SSPK) +32%.8x8 (EGHT) +32%.TG Therapeutics (TGTX) +31%.Peabody Energy (BTU) +29%...

Merger accelerates transformation to profitability, with estimated annual ized cost synergies of $15M beginning FY 2022 A ytu a dds Neos’ established, multi-brand ADHD portfolio, enhancing Aytu’s footprint in pediatrics and e...

Aytu BioScience (AYTU) and Neos Therapeutics (NEOS)  entered into a definitive merger agreement pursuant to which Neos will merge with a wholly owned subsidiary of Aytu in an all-stock transaction for ~$44.9M.Upon completion of the merger, Neos stockholders will be entitled to ...

Neos Therapeutics, Inc. (NEOS) Q3 2020 Earnings Conference Call November 9, 2020 8:30 AM ET Company Participants Richard Eisenstadt – Chief Financial Officer Jerry McLaughlin – Chief Executive Officer Conference Call Participants Jennifer Kim – Cantor Fitzgerald Jason But...

Neos Therapeutics (NEOS): Q3 GAAP EPS of -$0.10 misses by $0.05.Revenue of $12.54M (-28.5% Y/Y) misses by $2.93M.Press Release For further details see: Neos Therapeutics EPS misses by $0.05, misses on revenue

DALLAS and FORT WORTH, Texas, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq: NEOS), a commercial-stage pharmaceutical company developing and manufacturing central nervous system-focused products, today reported financial results for the third quarter ended September 30, ...

Vallon Pharmaceuticals has filed to raise $17 million in a U.S. IPO. The firm is developing reformulated drug treatment candidates for ADHD and narcolepsy. VALL is related to investor Arcturus Therapeutics, from whom it obtained its core technologies. For further details see...

DALLAS and FORT WORTH, Texas, Nov. 02, 2020 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq: NEOS), a commercial-stage pharmaceutical company developing and manufacturing central nervous system-focused products, today announced that it will report its third quarter 2020 financial result...

Are These At The Top Of Your Watch List This Week? Penny stocks remain one of the high points in the stock market today. After a huge breakout yesterday from WEI and previous to that, KXIN, there’s definitely a fervor for small-cap stocks right now. But there are more tha...